These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 18946626)

  • 1. Intramuscular neridronate in postmenopausal women with low bone mineral density.
    Adami S; Gatti D; Bertoldo F; Sartori L; Di Munno O; Filipponi P; Marcocci C; Frediani B; Palummeri E; Fiore CE; Costi D; Rossini M
    Calcif Tissue Int; 2008 Nov; 83(5):301-7. PubMed ID: 18946626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
    N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
    Deane A; Constancio L; Fogelman I; Hampson G
    BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis.
    Braga V; Gatti D; Colapietro F; Battaglia E; Righetti D; Prizzi R; Rossini M; Adami S
    Bone; 2003 Sep; 33(3):342-5. PubMed ID: 13678775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous neridronate in adults with osteogenesis imperfecta.
    Adami S; Gatti D; Colapietro F; Fracassi E; Braga V; Rossini M; Tatò L
    J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism.
    Rossini M; Viapiana O; Kalpakcioglu B; Dhangana R; Gatti D; Braga V; Fracassi E; Adami S
    Calcif Tissue Int; 2011 Jul; 89(1):21-8. PubMed ID: 21567168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
    Morabito N; Gaudio A; Lasco A; Catalano A; Atteritano M; Trifiletti A; Anastasi G; Melloni D; Frisina N
    J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.
    Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST
    Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
    Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
    J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial.
    Liu JH; Muse KN
    Am J Obstet Gynecol; 2005 Apr; 192(4):1316-23; discussion 1323-4. PubMed ID: 15846228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between the polymorphism of start codon and CDX2 site in vitamin D receptor gene and the effect of calcium supplementation on bone mineral density of postmenopausal women].
    Zhang ZL; He JW; Huang QR; Qin YJ; Hu YQ; Li M; Zhang H; Liu YJ; Hu WW
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Aug; 23(4):397-401. PubMed ID: 16883525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.